Chronic Myeloid Leukemia  >>  Phase 1
Welcome,         Profile    Billing    Logout  

29 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chronic Myeloid Leukemia
2012-005629-65: Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose-finding study

Ongoing
1
15
Europe
Iclusig, Film-coated tablet, Iclusig
University of Birmingham, Bloodwise TAP, Ariad Pharmaceuticals
Chronic Myeloid Leukaemia (CML) in Blast Phase, CML is a cancer of the white blood cells which build up, disrupting the normal balance of cells in the blood and bone marrow. In Blast phase, the cancer invades the bone marrow and other organs., Diseases [C] - Cancer [C04]
 
 
NCT02091245: Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Active, not recruiting
1
16
US
KPT-330, Selinexor
Dana-Farber Cancer Institute, William Lawrence and Blanche Hughes Foundation, Karyopharm Therapeutics Inc
Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL), Relapsed Acute Myelogenous Leukemia (AML), Refractory Acute Myelogenous Leukemia (AML), Relapsed Mixed Lineage Leukemia, Refractory Mixed Lineage Leukemia, Relapsed Biphenotypic Leukemia, Refractory Biphenotypic Leukemia, Chronic Myelogenous Leukemia (CML) in Blast Crisis
02/18
12/24
NCT02280525: Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

Completed
1
8
US
Lenalidomide, CC-5013, Revlimid, Rituximab, Rituxan, Fludarabine, Fludarabine Phosphate, Fludara, Cyclophosphamide, Cytoxan, Neosar, NK Cells, Cytarabine, Ara-C, Cytosar, DepoCyt, Cytosine Arabinosine Hydrochloride
M.D. Anderson Cancer Center, The Leukemia and Lymphoma Society, Celgene Corporation
Leukemia
07/19
07/19
CABL001X2101, NCT02081378: A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Completed
1
326
Europe, Japan, US, RoW
Asciminib (ABL001), ABL001, Nilotinib, Imatinib, Dasatinib
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
06/21
03/23
NCT03515512: IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Checkmark Safety data from trial for AML at ASH 2020
Dec 2020 - Dec 2020: Safety data from trial for AML at ASH 2020
Completed
1
23
US
Enasidenib, idhifa
Massachusetts General Hospital, Celgene
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
12/21
02/23
NCT03795779: CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Recruiting
1
20
RoW
CLL1-CD33 cCAR T cells
iCell Gene Therapeutics, The General Hospital of Western Theater Command, iCAR Bio Therapeutics Ltd., Peking University Shenzhen Hospital
Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Chronic Myeloid Leukemia
09/22
09/22
HQP1351CU101, NCT04260022: Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Recruiting
1
62
US
Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab, Blincyto
Ascentage Pharma Group Inc.
Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia
01/24
01/24
NCT03884829: A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

Recruiting
1
50
US
CYC140
Cyclacel Pharmaceuticals, Inc., M.D. Anderson Cancer Center
AML, Adult, Myelodysplastic Syndromes, ALL, Adult, CML, Refractory, CLL, Refractory
04/23
09/23
NCT03595917: ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

Recruiting
1
40
US
ABL001, Dasatinib, Sprycel, Prednisone, Blinatumomab
Marlise Luskin, MD, Novartis
B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
11/25
11/26
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Recruiting
1
106
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/26
01/27
CARDINAL, NCT06163430: - A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia

Not yet recruiting
1
80
US
TERN-701
Terns, Inc.
Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia
11/25
05/26
NCT05434312: TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

Recruiting
1
90
RoW
TGRX-678
Shenzhen TargetRx, Inc., Peking University People's Hospital
Chronic Myelogenous Leukemia
12/24
06/25
NCT05623774: A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

Recruiting
1
64
US
Imatinib Mesylate, IkT-001Pro
Inhibikase Therapeutics, Inc.
CML
12/23
03/24
NCT03533816: Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Recruiting
1
38
US
EAGD T-cell infusion (Phase I), CliniMACS-Prodigy, CliniMACS Alpha Beta T-Cell Depletion System, EAGD T-cell infusion (Expansion)
University of Kansas Medical Center, In8bio Inc.
Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
01/24
01/25
OGFT001-001, NCT03802695: A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Recruiting
1
186
US
OrcaGraft (Orca-Q)
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia
04/26
04/28
Precision-T, NCT04013685: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
1
255
US
Orca-T
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia
07/24
07/26
NCT05088356: Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Recruiting
1
40
US
Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Beneflur, SH T 586, fludarabine monophosphate, Melphalan, Melphalanum, CliniMACS CD34 Reagent System, Tacrolimus, Prograf, Advagraf, fujimycin, Cyclophosphamide, alkylating agent, Plerixafor, Mozobil, AMD 3100, LM-3100, Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent, filgrastim XM02, Thiotepa, Tepandina, Mycophenolate Mofetil (MMF), CellCept, Ruxolitinib, Jakafi
Stanford University, Orca Biosystems, Inc.
Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
12/25
12/25
NCT06398457: Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Not yet recruiting
1
8
NA
Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score, JH-DSA Semi-Quant Screen Score, JH-DSA Semi-Quant Response Score
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Janssen Research & Development, LLC
Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
06/26
12/26
NCT05016947: Venetoclax Plus Inotuzumab for B-ALL

Recruiting
1
26
US
Venetoclax, Venclexta, Dexamethasone, Decadron, Dexasone, Diodex, Hexadrol, Maxidex, Inotuzumab Ozogamicin, Besponsa
Dana-Farber Cancer Institute, AbbVie
B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL
07/24
06/26
NCT04771572: Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Recruiting
1
100
US
LP-118
Newave Pharmaceutical Inc
Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase
10/25
10/25
NCT06401603: A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia

Not yet recruiting
1
30
US
Decitabine, Dacogen, Listaftoclax, Olverembatinib
M.D. Anderson Cancer Center, Ascentage Pharma Group Inc.
Advanced Chronic Myeloid Leukemia, Philadelphia Chromosome-Positive Acute Myeloid Leukemia
01/27
01/29
NCT05367700: A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

Recruiting
1
108
RoW
HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion)
Jiangsu Hansoh Pharmaceutical Co., Ltd.
CML, Chronic Phase, CML, Accelerated Phase
12/24
09/26
CP-MGD024-01, NCT05362773: A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Recruiting
1
90
US
MGD024
MacroGenics
Leukemia, Acute Myeloid, Myelodysplastic Syndromes, Classical Hodgkin Lymphoma, Leukemia, B-cell, Leukemia, Hairy Cell, Mastocytosis, Aggressive Systemic, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia
03/25
03/25
NCT05107856: PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Terminated
1
21
US
PRT1419, Azacitidine, Venetoclax
Prelude Therapeutics
Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
01/24
01/24
MK-0482-002, NCT05038800: A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Terminated
1
12
Europe, US, RoW
MK-0482
Merck Sharp & Dohme LLC
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia
12/23
12/23
NCT04808115: IIT PH1 KDS-1001 in Patients With CML

Not yet recruiting
1
12
NA
KDS-1001
Lindsay Rein, MD, Kiadis Pharma
CML (Chronic Myelogenous Leukemia
09/25
09/27
ELVN-001-101, NCT05304377: A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Recruiting
1
180
Europe, Canada, US, RoW
ELVN-001
Enliven Therapeutics
Chronic Myeloid Leukemia
12/26
12/26
NCT06088888: TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia

Recruiting
1
90
US
TGRX-678
Shenzhen TargetRx, Inc., M.D. Anderson Cancer Center
Chronic Myelogenous Leukemia
03/27
06/27
NCT05823571: Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Recruiting
1
32
US
Itacitinib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation
Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic, T-cell Prolymphocytic Leukemia, CML, Myeloproliferative Disorders, Multiple Myeloma, Plasma Cell Leukemia
03/28
03/30

Download Options